Vaccines against mucosal infections

Current Opinion in Immunology

Volumn 24, Issue 3, 2012, Pages 343-353

  Holmgren, Jan ^a   Svennerholm, Ann Mari ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; MUTACHOL; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; ORC VAX; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; SHANCHOL; SWINE INFLUENZA VACCINE; TYPHOID VACCINE; TYPHRIX; UNCLASSIFIED DRUG; VACCINE; VEROPOL;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; BACTERIAL TRANSMISSION; CHOLERA; CROSS PROTECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; ENTEROTOXIGENIC ESCHERICHIA COLI; EPIDEMIC; HUMAN; IMMUNOGENICITY; INFECTION; INFLAMMATION; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; INTUSSUSCEPTION; MEMBRANE PERMEABILITY; MUCOSAL ADMINISTRATION; MUCOSAL DISEASE; MUCOSAL IMMUNITY; MUCOSAL INFECTION; NONHUMAN; POLIOMYELITIS; REVIEW; ROTAVIRUS INFECTION; SEROCONVERSION; SINGLE DRUG DOSE; TYPHOID FEVER; VIBRIO CHOLERAE;

ANIMALS; HUMANS; IMMUNITY, MUCOSAL; MUCOUS MEMBRANE; VACCINES;

EID: 84862674538     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.03.014     Document Type: Review

References (78)

1. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., Jha P., Campbell H., Walker C.F., Cibulskis R., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375:1969-1987.
2. Holmgren J., Kaper J. Oral cholera vaccines. New Generation Vaccines 2010, 506-515. Informa Health Care, New York, USA. edn 4. M.M. Levine (Ed.).
3. Ogra P.L., Okayasu H., Czerkinsky C., Sutter R.W. Mucosal immunity to poliovirus. Expert Rev Vaccines 2011, 10:1389-1392.
4. Svennerholm A.M., Holmgren J., Hanson L.A., Lindblad B.S., Quereshi F., Rahimtoola R.J. Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Scand J Immunol 1977, 6:1345-1349.
5. Svennerholm A.M., Hanson L.A., Holmgren J., Jalil F., Lindblad B.S., Khan S.R., Nilsson A., Svennerholm B. Antibody responses to live and killed poliovirus vaccines in the milk of Pakistani and Swedish women. J Infect Dis 1981, 143:707-711.
6. Czerkinsky C., Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol 2012, 354:1-18.
7. Mutreja A., Kim D.W., Thomson N.R., Connor T.R., Lee J.H., Kariuki S., Croucher N.J., Choi S.Y., Harris S.R., Lebens M., et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature 2011, 477:462-465.
8. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Neogy P.K., Stanton B., Huda N., Khan M.U., Kay B.A., Khan M.R., et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988, 158:372-377.
9. Peltola H., Siitonen A., Kyronseppa H., Simula I., Mattila L., Oksanen P., Kataja M.J., Cadoz M. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991, 338:1285-1289.
10. Scerpella E.G., Sanchez J.L., Mathewson I.J., Torres-Cordero J.V., Sadoff J.C., Svennerholm A.M., DuPont H.L., Taylor D.N., Ericsson C.D. Safety, immunogenicity, and protective efficacy of the Whole-Cell/recombinant B Subunit (WC/rBS) oral cholera vaccine against travelers' diarrhea. J Travel Med 1995, 2:22-27.
11. Clemens J., Shin S., Sur D., Nair G.B., Holmgren J. New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol 2011, 8:701-710.
12. Sur D., Kanungo S., Sah B., Manna B., Ali M., Paisley A.M., Niyogi S.K., Park J.K., Sarkar B., Puri M.K., et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 2011, 5:e1289.
13. Siddique A.K., Nair G.B., Alam M., Sack D.A., Huq A., Nizam A., Longini I.M., Qadri F., Faruque S.M., Colwell R.R., et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 2010, 138:347-352.
14. Richie E.E., Punjabi N.H., Sidharta Y.Y., Peetosutan K.K., Sukandar M.M., Wasserman S.S., Lesmana M.M., Wangsasaputra F.F., Pandam S.S., Levine M.M., et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000, 18:2399-2410.
15. Ali M., Emch M., von Seidlein L., Yunus M., Sack D.A., Rao M., Holmgren J., Clemens J.D. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005, 366:44-49.
16. Longini I.M., Nizam A., Ali M., Yunus M., Shenvi N., Clemens J.D. Controlling endemic cholera with oral vaccines. PLoS Med 2007, 4:e336.
17. WHO Publication Cholera vaccines: WHO position paper-Recommendations. Vaccine 2010, 28:4687-4688.
18. Chao D.Y., Cheng K.F., Hsieh Y.H., Li T.C., Wu T.N., Chen C.Y., Tsai C.A., Chen J.H., Chiu H.T., Lu J.J., et al. Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine. Vaccine 2011, 29:617-623.
19. Mukandavire Z., Liao S., Wang J., Gaff H., Smith D.L., Morris J.G. Estimating the reproductive numbers for the 2008-2009 cholera outbreaks in Zimbabwe. Proc Natl Acad Sci USA 2011, 108:8767-8772.
20. Anh D.D., Lopez A.L., Thiem V.D., Grahek S.L., Duong T.N., Park J.K., Kwon H.J., Favorov M., Hien N.T., Clemens J.D. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis 2011, 5:e1006.
21. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82:346-353.
22. Fraser A., Paul M., Goldberg E., Acosta C.J., Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007, 25:7848-7857.
23. Sinha A., Sazawal S., Kumar R., Sood S., Reddaiah V.P., Singh B., Rao M., Naficy A., Clemens J.D., Bhan M.K. Typhoid fever in children aged less than 5 years. Lancet 1999, 354:734-737.
24. Brooks W.A., Hossain A., Goswami D., Nahar K., Alam K., Ahmed N., Naheed A., Nair G.B., Luby S., Breiman R.F. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005, 11:326-329.
25. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999, 17(Suppl. 2):S22-S27.
26. Ohtake S., Martin R., Saxena A., Pham B., Chiueh G., Osorio M., Kopecko D., Xu D., Lechuga-Ballesteros D., Truong-Le V. Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines. Vaccine 2011, 29:2761-2771.
27. Yang H.H., Wu C.G., Xie G.Z., Gu Q.W., Wang B.R., Wang L.Y., Wang H.F., Ding Z.S., Yang Y., Tan W.S., et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001, 79:625-631.
28. Sur D., Ochiai R.L., Bhattacharya S.K., Ganguly N.K., Ali M., Manna B., Dutta S., Donner A., Kanungo S., Park J.K., et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009, 361:335-344.
29. Szu S.C., Stone A.L., Robbins J.D., Schneerson R., Robbins J.B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med 1987, 166:1510-1524.
30. Canh D.G., Lin F.Y., Thiem V.D., Trach D.D., Trong N.D., Mao N.D., Hunt S., Schneerson R., Robbins J.B., Chu C., et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 2004, 72:6586-6588.
31. Thiem V.D., Lin F.Y., Canh do G., Son N.H., Anh D.D., Mao N.D., Chu C., Hunt S.W., Robbins J.B., Schneerson R., et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011, 18:730-735.
32. van Damme P., Kafeja F., Anemona A., Basile V., Hilbert A.K., De Coster I., Rondini S., Micoli F., Qasim Khan R.M., Marchetti E., et al. Safety, immunogenicity and dose ranging of a new Vi-CRM conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS ONE 2011, 6:e25398.
33. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:136-141.
34. Simpson E., Wittet S., Bonilla J., Gamazina K., Cooley L., Winkler J.L. Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries. BMC Public Health 2007, 7:281.
35. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., Cheuvart B., Espinoza F., Gillard P., Innis B.L., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
36. Kawai K., O'Brien M.A., Goveia M.G., Mast T.C., El Khoury A.C. Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review. Vaccine 2012, 30:1244-1254.
37. Parashar U.D., Gibson C.J., Bresse J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12:304-306.
38. Clements-Mann M.L., Dudas R., Hoshino Y., Nehring P., Sperber E., Wagner M., Stephens I., Karron R., Deforest A., Kapikian A.Z. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 2001, 19:4676-4684.
39. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., Zanardi L.R., Setia S., Fair E., LeBaron C.W., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344:564-572.
40. Hagbom M., Istrate C., Engblom D., Karlsson T., Rodriguez-Diaz J., Buesa J., Taylor J.A., Loitto V.M., Magnusson K.E., Ahlman H., et al. Rotavirus stimulates release of serotonin (5-HT) from human enterochromaffin cells and activates brain structures involved in nausea and vomiting. PLoS Pathog 2011, 7:e1002115.
41. Ward R.L., Clark H.F., Offit P.A. Influence of potential protective mechanisms on the development of live rotavirus vaccines. J Infect Dis 2010, 202(Suppl.):S72-S79.
42. Gladstone B.P., Ramani S., Mukhopadhya I., Muliyil J., Sarkar R., Rehman A.M., Jaffar S., Gomara M.I., Gray J.J., Brown D.W., et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011, 365:337-346.
43. Pawinski R., Debrus S., Delem A., Smolenov I., Suryakiran P.V., Han H.H. Rotarix in developing countries: paving the way for inclusion in national childhood immunization programs in Africa. J Infect Dis 2010, 202(Suppl.):S80-S86.
44. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., Binka F.N., Steele A.D., Laserson K.F., Ansah N.A., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
45. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., Dallas M.J., Heyse J.F., Goveia M.G., Black S.B., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
46. Wang Y., Azevedo M., Saif L.J., Gentsch J.R., Glass R.I., Jiang B. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine 2010, 28:5432-5436.
47. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., Simmerman J.M., Gordon A., Sato M., Howie S., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378:1917-1930.
48. Treanor J.K.W., Stephenson I. Influenza. New Generation Vaccines 2010, 532-556. Informa Health Care, New York, USA. edn 4. M.M. Levine (Ed.).
49. Ge S., Wang Z. An overview of influenza A virus receptors. Crit Rev Microbiol 2011, 37:157-165.
50. Carter N.J., Curran M.P. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71:1591-1622.
51. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
52. Rudenko L., van den Bosch H., Kiseleva I., Mironov A., Naikhin A., Larionova N., Bushmenkov D. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 2011, 29(Suppl. 1):A40-A44.
53. CDC Update on vaccine-derived polioviruses worldwide, July 2009-2011. MMWR Morb Mortal Wkly Rep 2011, 60:846-850.
54. Okayasu H., Sutter R.W., Czerkinsky C., Ogra P.L. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine 2011, 29:8205-8214.
55. Waggie Z., Geldenhuys H., Sutter R.W., Jacks M., Mulenga H., Mahomed H., De Kock M., Hanekom W., Pallansch M.A., Kahn A.L., et al. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. J Infect Dis 2012, 205:228-236.
56. Gnanashanmugam D., Troy S.B., Musingwini G., Huang C., Halpern M.S., Stranix-Chibanda L., Shetty A.K., Kouiavskaia D., Nathoo K., Chumakov K., et al. Immunologic response to oral polio vaccine in human immunodeficiency virus-infected and uninfected Zimbabwean children. Pediatr Infect Dis J 2012, 31:176-180.
57. Bonnet M.C., Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008, 26:4978-4983.
58. Paul Y. Herd immunity and herd protection. Vaccine 2004, 22:301-302.
59. Liao G., Li R., Li C., Sun M., Li Y., Chu J., Jiang S., Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012, 205:237-243.
60. Cadorna-Carlos J., Vidor E., Bonnet M.C. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis 2012, 16:e110-e116.
61. Humphrey J.H. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 2009, 374:1032-1035.
62. Kau A.L., Ahern P.P., Griffin N.W., Goodman A.L., Gordon J.I. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
63. Sack D.A., Qadri F., Svennerholm A.-M. Determinants of responses to oral vaccines in developing countries. Ann Nestle' (Engl) 2008, 66:71-79.
64. Albert M.J., Qadri F., Wahed M.A., Ahmed T., Rahman A.S., Ahmed F., Bhuiyan N.A., Zaman K., Baqui A.H., Clemens J.D., et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis 2003, 187:909-913.
65. Ahmed T., Svennerholm A.M., Al Tarique A., Sultana G.N., Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 2009, 27:1433-1439.
66. Cooper P.J., Chico M.E., Losonsky G., Sandoval C., Espinel I., Sridhara R., Aguilar M., Guevara A., Guderian R.H., Levine M.M., et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis 2000, 182:1199-1206.
67. Desai S.N., Clemens J.D. An overview of cholera vaccines and their public health implications. Curr Opin Pediatr 2012, 24:85-981.
68. Clemens J.D., Sack D.A., Harris J.R., Van Loon F., Chakraborty J., Ahmed F., Rao M.R., Khan M.R., Yunus M., Huda N., et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990, 335:270-273.
69. Sanchez J.L., Vasquez B., Begue R.E., Meza R., Castellares G., Cabezas C., Watts D.M., Svennerholm A.M., Sadoff J.C., Taylor D.N. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994, 344:1273-1276.
70. Lucas M.E., Deen J.L., von Seidlein L., Wang X.Y., Ampuero J., Puri M., Ali M., Ansaruzzaman M., Amos J., Macuamule A., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005, 352:757-767.
71. Klugman K.P., Gilbertson I.T., Koornhof H.J., Robbins J.B., Schneerson R., Schulz D., Cadoz M., Armand J. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987, 2:1165-1169.
72. Acharya I.L., Lowe C.U., Thapa R., Gurubacharya V.L., Shrestha M.B., Cadoz M., Schulz D., Armand J., Bryla D.A., Trollfors B., et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. New Engl J Med 1987, 317:1101-1104.
73. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., Kossaczka Z., Bryla D.A., Shiloach J., Robbins J.B., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. New Engl J Med 2001, 344:1263-1269.
74. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., Podder G., Vu D.T., Le T.P., Luby S.P., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
75. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., Gonzalez A., Malespin O., Amador J.J., Umana J., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301:2243-2251.
76. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., Meurice F., Han H.H., Damaso S., Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
77. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., Ngwira B., Victor J.C., Gillard P.H., Cheuvart B.B., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
78. de Palma O., Cruz L., Ramos H., de Baires A., Villatoro N., Pastor D., de Oliveira L.H., Kerin T., Bowen M., Gentsch J., et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010, 340:c2825.